M. D. Anderson Cancer Center - News Releases 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.MD Anderson named top-ranked hospital for cancer care
The University of Texas MD Anderson Cancer Center has been ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report's "Best Hospitals" survey. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - July 21, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson study finds one-third of colorectal cancers diagnosed before age 35 are hereditary
Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - July 20, 2015 Category: Cancer & Oncology Source Type: news
Can protein 14-3-3 sigma prevent or kill breast cancer tumors?
MD Anderson study shows potential of simple molecule in cancer metabolism
Every parent knows the maxim "feed a cold, starve a fever." In cancer, however, exactly how to feed or starve a tumor has not been easy to determine. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - July 16, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson names new vice provost, clinical and interdisciplinary research
The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, M.D., as vice provost for clinical and interdisciplinary research. Dr. Wilding's appointment at MD Anderson will begin on September 1st. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 30, 2015 Category: Cancer & Oncology Source Type: news
Similarities between embryos and breast tumors identified
MD Anderson researchers find that metastatic tumors behave like embryonic stem cells
It may seem incredulous, but breast tumors may have something in common with embryos ... at least in mice, say researchers at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 30, 2015 Category: Cancer & Oncology Source Type: news
Keys to prevention: MD Anderson leaders share latest news in fight to end cancer
The University of Texas MD Anderson Cancer Center heads to Aspen this summer for its 17th annual Making Cancer History® seminar. The free event is slated for 1-3 p.m. on July 16 at Aspen Meadows Resort's Paepcke Auditorium, 1000 N. Third St. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 24, 2015 Category: Cancer & Oncology Source Type: news
Tiny particles in blood useful for early diagnosis of pancreatic cancer
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 24, 2015 Category: Cancer & Oncology Source Type: news
Current blood cancer drug prices not justified, MD Anderson study finds
The costs associated with cancer drug prices have risen dramatically
over the past fifteen years, which is of concern to many top
oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center
concluded the majority of existing treatments for hematologic, or
blood, cancers are currently priced too high to be considered
cost-effective in the United States. Their findings are published in the
current issue of the journal Cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 23, 2015 Category: Cancer & Oncology Source Type: news
Genomic discovery of skin cancer subtypes provides potential 'signpost' for drug targets
Cutaneous melanoma, the most deadly form of skin cancer, is now believed
to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 18, 2015 Category: Cancer & Oncology Source Type: news
Breast-Conserving Therapy for Early-stage Cancers has Increased Substantially, Though Access Remains an Issue
The first comprehensive national review of breast-conserving therapy
(BCT) shows that over the last 13 years rates of this treatment modality
for early-stage breast cancer have increased at a steady pace. However,
the review also highlights important demographic factors that impact
which patients have access to BCT. Researchers at The University of Texas MD Anderson Cancer Center
found declines in disparities related to age, treatment facility type
and geographic region, but also identified several socioeconomic factors
- insurance, income and travel distance to treatment centers - as key
barriers to BCT. (Source: ...
Source: M. D. Anderson Cancer Center - News Releases - June 17, 2015 Category: Cancer & Oncology Source Type: news
What's in a name? "Death-associated protein" promotes cancer growth in most aggressive breast cancers
Although traditionally understood to induce death in cancer cells, researchers atThe University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 15, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson study finds gene mutations sensitize tumors to specific cancer drugs
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 11, 2015 Category: Cancer & Oncology Source Type: news
ADAMTS family of genes may be the next 'thing' in ovarian cancer treatment
There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 11, 2015 Category: Cancer & Oncology Source Type: news
Multi-center study redefines brain tumor diagnosis and treatment
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 10, 2015 Category: Cancer & Oncology Source Type: news
Yin and yang: Immune signaling protein has opposing roles in breast cancer development
Countering previously held beliefs, researchers at The University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers. This is because TLR4 can either promote or inhibit breast cancer cell growth depending on mutations in a gene called TP53. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - June 8, 2015 Category: Cancer & Oncology Source Type: news
